Compass Therapeutics, Inc. · NASDAQ:CMPX
Compass Therapeutics — Investor Presentation (July 2026)
45 slides from Compass Therapeutics's investor presentation, Jul 1, 2026
Slide 1: Bringing Transformative Oncology Therapies to Patients
1 Nasdaq: CMPX Bringing Transformative Oncology Therapies to Patients Corporate Presentation I July 2026
Slide 2: This presentation has been prepared by Compass Therapeutics, Inc . ("we," "us," "our," or
2 This presentation has been prepared by Compass Therapeutics, Inc . ("we," "us," "our," or the “Company”) . Statements contained herein are made as of the date of this presentation unless stated otherwise, and this presentation shall not under any circumstances create an implication that the inform
Slide 3: A Leader in Next-Generation Oncology Therapies
3 A Leader in Next - Generation Oncology Therapies Bispecific antibody targeting DLL4 x VEGF - A Next - generation angiogenesis inhibitor Phase 2/3 study in patients with BTC met primary / key secondary endpoints Planning to file BLA based on data with potential approval in 2H 2027 $3B+ addressable
Slide 4: Milestones: Diversified & Robust Pipeline with Multiple Value Inflection Points
4 Milestones Phase 3 Phase 2 Phase 1 Preclinical Target Program Q3 26: Meet with FDA Q4 26: Submit BLA DLL4 x VEGF - A Tovecimig Planning Phase 2 based on BTC efficacy data (potential: g astric , ovarian, CRC, renal, HCC) Mid - 26: Initiate Phase 2 CD137 (4 - 1BB) CTX - 471 H2 26: Phase 1 cohort exp
Slide 5: Tovecimig (CTX-009) DLL4 x VEGF-A bispecific antibody
5 Nasdaq: CMPX Tovecimig (CTX - 009) DLL4 X VEGF - A bispecific antibody
Slide 6: Tovecimig: Dual Targeting of DLL4 and VEGF to Maximize Anti-Angiogenesis
6 Tovecimig : Dual Targeting of DLL4 and VEGF to Maximize Anti - Angiogenesis 1. PMID: 17457300; 2. PMID: 21923938; 3. PMID: 27049350 Anti - VEGF - A disrupts tumor vessel formation (a validated anti - angiogenic mechanism) while anti - DLL4 targets DLL4 - Notch 1 signali ng and alters perfusion in
Slide 7: Strong Monotherapy Activity in Multiple Refractory Tumor Types
7 n=40 evaluable dosed at 0.3 - 17.5 mg/kg n=40 evaluable dosed at 10 mg/kg Demonstrated monotherapy activity in patients with advanced colorectal cancer and gastric cancer -50 -40 -30 -20 -10 0 10 20 30 40 50 60 Strong Monotherapy Activity in Multiple Refractory Tumor Types 1. AACR - NIH - EORTC 20
Slide 8: Strong Combination Activity in Multiple Refractory Tumor Types
8 Strong activity in combination with paclitaxel, particularly in patients with BTC , led to a Phase 2/3 study Strong Combination Activity in Multiple Refractory Tumor Types 1. CCA Summit 2023; 2. ASCO GI 2023 Meeting Phase 2 – Advanced BTC 2 Investigator - assessed responses in single - arm study,
Slide 9: Pivotal Phase 2/3 COMPANION-002 Trial in BTC Study Design
9 Paclitaxel 80 mg/m 2 Days 1, 8 and 15 of every 28 - day cycle Tovecimig 10mg/kg Days 1 and 15 Paclitaxel 80 mg/m 2 Days 1, 8 and 15 of every 28 - day cycle Pivotal Phase 2/3 COMPANION - 002 Trial in BTC Study Design * As confirmed by Blinded Independent Central Radiology (BICR) Review ECOG = Easte
Slide 10: COMPANION-002: Well-Balanced Baseline Demographics
10 COMPANION - 002: Well - Balanced Baseline Demographics Paclitaxel (n=57) Tovecimig + Paclitaxel (n=111) 63.0 65.0 Median (years) Age 24 (42.1) 53 (47.7) Male Sex 33 (57.9) 58 (52.3) Female 10 (17.5) 17 (15.3) Asian Race 40 (70.2) 84 (75.7) White 6 (10.5) 4 (3.6) African American 1 (1.8) 6 (5.4) U
Slide 11: COMPANION-002: Significant Improvement in Primary Endpoint of ORR
11 Paclitaxel Tovecimig + Paclitaxel n=57 n=111 Intent - to - Treat Population 3 (5.3%) 20 (18.0%) Overall Response Rate (CR+PR) p=0.0228 Two - Sided p - value 0 (0.0%) 1 (0.9%) Complete Response (CR) 3 (5.3%) 19 (17.1%) Partial Response (PR) 18 (31.6%) 49 (44.1%) Stable Disease (SD) 2 (3.5%) 8 (7.2
Slide 12: COMPANION-002: Tovecimig Significantly Improved PFS (BICR-Assessed)
12 COMPANION - 002: Tovecimig Significantly Improved PFS (BICR - Assessed) Data cutoff from COMPANION - 002 as of April 2026. Tovecimig + paclitaxel Paclitaxel alone Censored Tovecimig + paclitaxel Paclitaxel alone ITT Analysis: HR=0.44, p<0.0001, 4.7 vs. 2.6 months median PFS
Slide 13: COMPANION-002: OS Analysis Confounded by Crossover
13 COMPANION - 002: OS Analysis Confounded by Crossover Data cutoff from COMPANION - 002 as of April 2026. ITT analysis: HR=1.05, p=0.78, 8.9 vs. 9.4 months median OS Control arm includes: 31 patients (54%) who crossed over and received tovecimig plus paclitaxel (with a median OS of 12.8 months) 26
Slide 14: COMPANION-002: Tovecimig Improved PFS2 Post-Crossover
14 COMPANION - 002: Tovecimig Improved PFS2 Post - Crossover Data cutoff from COMPANION - 002 as of April 2026. Prespecified secondary analysis (n=31): HR=0.36, p =0.065, 3.5 vs. 1.9 months median PFS
Slide 15: COMPANION-002: Tovecimig Significantly Improved OS in Crossover Patients
15 COMPANION - 002: Tovecimig Significantly Improved OS in Crossover Patients Data cutoff from COMPANION - 002 as of April 2026. Post hoc subset analysis (n=31 vs. n=26): HR=0.54, p=0.04, 12.8 vs. 6.1 months median OS
Slide 16: COMPANION-002: Crossover Patients Progressed Faster on Paclitaxel Monotherapy
16 COMPANION - 002: Crossover Patients Progressed Faster on Paclitaxel Monotherapy than Patients Who Did Not Crossover Data cutoff from COMPANION - 002 as of April 2026. Post hoc subset analysis (n=31 vs. n=26): 1.9 vs. 3.6 months median PFS, p=0.007
Slide 17: COMPANION-002: Adverse Events
17 Paclitaxel n=53 Tovecimig + Paclitaxel n=108 Related ≥ Grade 3 ≥ Grade 3 Related Overall Related ≥ Grade 3 ≥ Grade 3 Related Overall n (%) 2 (4) 3 (6) 23 (43) 24 (45) 12 (11) 16 (15) 66 (61) 72 (67) Fatigue 1 (2) 3 (6) 2 (4) 10 (19) 48 (44) 56 (52) 65 (60) 75 (69) Hypertension 14 (26) 14 (26) 20
Slide 18: COMPANION-002: Study Summary and Next Steps
18 COMPANION - 002: Study Summary and Next Steps Results Endpoint / Analysis Significant improvement : 18.0% vs 5.3% BICR - assessed ORR (p=0.0228) Primary ORR Significant improvement : 4.7 vs 2.6 months median PFS (HR=0.44, p<0.0001) Key Secondary PFS OS confounded by crossover : 8.9 vs 9.4 months
Slide 19: Tovecimig: Potential to Become Standard of Care in 2L BTC
19 ORR N Program Analysis 18.0% (p=0.0228) 111 Combo Tovecimig + Paclitaxel ITT 5.3% 57 Control 31 Crossover Patients Initially Randomized to Paclitaxel Subset 26 Paclitaxel 4.0% 59 FOLFIRI Choi - 2021 1 2L 5.9% 59 FOLFOX 0 2 4 6 8 10 12 14 Tovecimig: Potential to Become Standard of Care in 2L BTC P
Slide 20: Tovecimig (CTX-009) Commercial Opportunity
20 Nasdaq: CMPX Tovecimig (CTX - 009) Commercial Opportunity
Slide 21: Significant Unmet Need in Biliary Tract Cancer Treatment Remains
21 Significant Unmet Need in Biliary Tract Cancer Treatment Remains Despite Recent Advances BTC is a group of aggressive malignancies originating in the bile ducts (cholangiocarcinoma) or gallbladder Common hepatic duct Left hepatic duct Right hepatic duct Intrahepatic bile ducts Right lobe of liver
Slide 22: Targeted Launch in a Potential TAM of Over $3 Billion
22 Treatment Landscape Allows for a Targeted Launch in a Potential Total Addressable Market (TAM) of Over $3 Billion * As identified by the Cholangiocarcinoma Foundation (CCF) Over 15K patients/yr potentially eligible for tovecimig Concentrated treatment landscape of BTC >26,500 1,2 patients diagnos
Slide 23: Significant Expansion Opportunity for Tovecimig Beyond 2L BTC
23 Significant Expansion Opportunity for Tovecimig Beyond 2L BTC 1. Seer database (BTC, CRC, Ovarian); 2. Cancer.org (Gastric, HCC); 3. PMID: 41092086 (GBM); 4. PMID: 32644401 (RCC); 5. PMID: 3622354; 6. Avastin prescribing information; 7. PM ID: 25103711; 8. https://www.accessdata.fda.gov/drugsatfd
Slide 24: Tovecimig – Advancing to Approval in BTC and Beyond
24 Tovecimig – Advancing to Approval in BTC and Beyond Strong Clinical Data in a Difficult Indication Robust evidence of activity in patients with BTC Generally well tolerated, with no new safety signal No approved therapeutics for most patients in 2L setting Near - Term Regulatory Milestones Expect
Slide 25: CTX-8371 PD-1 x PD-L1 bispecific antibody
25 Nasdaq: CMPX CTX - 8371 PD - 1 x PD - L1 bispecific antibody
Slide 26: PD-1 and PD-L1 are Validated Targets, Yet Unmet Needs Remain
26 1. PMID: 39887747; 2. PMID: 36636451; 3. https:// www.healio.com /news/hematology - oncology/20250327/only - 1 - in - 5 - people - treated - with - immune - checkpoint - inhibitors - respond - to - therapy; 4. https://www.gminsights.com/industry - analysis/immune - checkpoint - inhibitors - marke
Slide 27: CTX-8371: Identified Using StitchMabs Platform
27 Superior Activity Proprietary Structural Design Engineered S ynergistic A ctivity of PD - 1 / PD - L1 in StitchMabs format CTX - 8371: Identified Using StitchMabs Platform Mixed lymphocyte reaction (MLR) assay Pembro / Atezo Stitch M ab s Nivo / Atezo Stitch M ab s Pembro + Atezo Cocktail Nivo +
Slide 28: Novel Mechanism of Action Leads to Amplified Anti-Tumor T Cell Activity
28 Novel Mechanism of Action Leads to Amplified Anti - Tumor T Cell Activity PMID: 38379869
Slide 29: CTX-8371: Ongoing Phase 1 Study
29 CTX - 8371: Ongoing Phase 1 Study Phase 1 dose escalation data at ASCO 2026 Inclusion Criteria Post - PD - 1 or PD - L1 patients with NSCLC, TNBC, HL, HNSCC, or melanoma Part A: Dose Escalation Part B: Dose Expansion 0.1mg/kg n=3 - 6 0.3mg/kg n=3 - 6 1.0mg/kg n=3 - 6 3.0mg/kg n=3 - 6 10.0 mg/kg n
Slide 30: CTX-8371 in TNBC: Confirmed, Deep and Durable Partial Response
30 CTX - 8371 in TNBC: Confirmed, Deep and Durable Partial Response Right Lobe Nodule Pericardial Mass >90% reduction in target tumor lesions in one patient (4 th line) 87 mm total target lesions at baseline (3 target lesions) Triple - Negative Breast Cancer Baseline 20 mm 52 mm Week 8 0 mm 0 mm Wee
Slide 31: CTX-8371 in HL: Metabolic Partial Response
31 CTX - 8371 in HL: Metabolic Partial Response Reduction of Deauville Score from 5 at Baseline to 3 at Week 24 Periportal Node AC Node Peripancreatic Node Baseline Week 24 Previously treated with: ABVD (1L) BEAM/stem cell transplant (2L) nivolumab/brentuximab (3L)
Slide 32: CTX-8371 in NSCLC: Complete Resolution of Target Lesions
32 CTX - 8371 in NSCLC: Complete Resolution of Target Lesions Non - Small Cell Lung Cancer Complete resolution of target tumor lesions in one patient after initial pseudo - progression 4 th line with 59 mm total target lesion burden @ baseline Previously treated with: Baseline Week 8 Week 16 45 mm 1
Slide 33: CTX-10726 PD-1 x VEGF-A bispecific antibody
33 Nasdaq: CMPX CTX - 10726 PD - 1 x VEGF - A bispecific antibody
Slide 34: CTX-10726: Potential Best-in-Class PD-1 x VEGF-A Bispecific
34 1. SITC Annual Meeting 2025 CTX - 10726 : Potential Best - in - Class PD - 1 x VEGF - A Bispecific Transgenic Mouse Model (MC38) (express human PD - 1/PD - L1) Human NSCLC (HCC827) Xenografts 1 Treated with human PBMCs and indicated antibodies Testing both PD - 1 and VEGF - A targeting Treatment
Slide 35: Phase 1 Study Design of CTX-10726
35 Phase 1 of CTX - 10726 Study Design CTX - 10726 Single Agent Dose Escalation CTX - 10726 Single Agent Dose Expansion Dose Level(s) and Tumor Types TBD n=40 Study initiated in Q1 2026 with topline data expected in H2 2026 Inclusion Criteria Cohort 1 Cohort 2 DLT Evaluation Period ~4 weeks 0.3mg/kg
Slide 36: CTX-471 CD137 agonist
36 Nasdaq: CMPX CTX - 471 CD137 agonist
Slide 37: Response to CTX-471 was Associated with High NCAM Expression
37 Response to CTX - 471 was Associated with High NCAM Expression in the Phase 1 Study 4 PRs M elanoma (3 of 11) & Mesothelioma (1 of 4) 1 CR S mall cell lung cancer (1 of 3) Patients with clinical benefit from CTX - 471 had high expression of NCAM (CD56), highlighting its potential as patient - sel
Slide 38: CTX-471: Complete Response in a Patient with Small Cell Lung Cancer
38 Small Cell Lung Melanoma Melanoma Melanoma Head and Neck Head and Neck CTX - 471: Complete Response in a Patient with Small Cell Lung Cancer CTX - 471 treated patient with advanced SCLC had a PET negative complete response after ~3 years on therapy Previously treated with: carboplatin/etoposide p
Slide 39: CTX-471: Novel Mechanism of Action for NCAM (CD56)+ Tumors
39 CTX - 471: Novel Mechanism of Action for NCAM (CD56)+ Tumors
Slide 40: Phase 2 Study Design of CTX-471 in Patients with NCAM+ Tumors
40 Phase 2 Study Design of CTX - 471 in Patients with NCAM+ Tumors Eligibility Criteria: • Patients with locally advanced or metastatic Grade 3 neuroendocrine tumors (NET) or neuroendocrine carcinomas (NEC) • Tumor must be centrally confirmed as NCAM positive by immunohistochemical staining • Must h
Slide 41: NCAM Positive Tumors Represent a Significant Opportunity for CTX-471
41 NCAM Positive Tumors Represent a Significant Opportunity for CTX - 471 1,500 2,400 2,900 3,200 5,600 14,700 37,000 67,300 Colon NET NSCLC NET Prostate NET Pancreatic NET Metastatic/ Melanoma Glioblastoma* SCLC* Total US 2023 – SEER Database 1 * ~100% NCAM+ 1. Seer database
Slide 42: Milestones
42 Nasdaq: CMPX Milestones
Slide 43: Key Anticipated Milestones
43 Key Anticipated Milestones Tovecimig BTC (DLL4 x VEGF - A) Tovecimig (DLL4 x VEGF - A) CTX - 471 (CD137) CTX - 8371 (PD - 1 x PD - L1) CTX - 10726 (PD - 1 x VEGF - A) 2025 1H 2026 2H 2026 Ph 2/3 Data (2L) ORR Initiated Ph 2 IST (1L) 3 Deep Responses NSCLC, TNBC, HL (post - checkpoint inhibitor) P
Slide 44: Leadership Team
44 Thomas J. Schuetz, MD, PhD President, CEO, & Vice Chairman of the Board Barry Shin , J D, MBA Chief Financial Officer Arjun Prasad, MBA, MPH Chief Commercial Officer Cynthia Sirard, MD Chief Medical Officer Bing Gong, PhD Chief Scientific Officer Jon Anderman, JD General Counsel & Corporate Secre
Slide 45: Compass Therapeutics
45 Nasdaq: CMPX Compass Therapeutics Website: compasstherapeutics.com Nasdaq: CMPX
Compass Therapeutics — Investor Presentation (July 2026) on 6ix